News und Analysen
EQS-News: Verbio SE: Verbio achieves forecast earnings in FY 2023/24 and marks important milestones
EQS-News: Verbio SE: Verbio achieves forecast earnings in FY 2023/24 and marks important milestones
EQS-Adhoc: Verbio SE: Verbio forecasts EBITDA of EUR 120 million to EUR 160 million for the financial year 2024/25
EQS-Adhoc: Verbio SE: Verbio forecasts EBITDA of EUR 120 million to EUR 160 million for the financial year 2024/25
EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
EQS-News: Verbio welcomes the preliminary results of anti-dumping proceedings
EQS-News: Verbio welcomes the preliminary results of anti-dumping proceedings
EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
EQS-News: Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
EQS-News: Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
EQS-News: Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
EQS-News: Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
EQS-News: Eckert & Ziegler receives “Best Managed Companies Award”
EQS-News: Q3 2023/24: Volatile market environment affects earnings
EQS-News: Q3 2023/24: Volatile market environment affects earnings
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
EQS-News: Eckert & Ziegler Completes Change of Legal Form to SE
EQS-News: Eckert & Ziegler Completes Change of Legal Form to SE
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan
EQS-News: Q2 2023/24: Verbio holds its own in a volatile market environment
EQS-News: Q2 2023/24: Verbio holds its own in a volatile market environment
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177
EQS-News: Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
EQS-News: Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
EQS-Adhoc: Verbio SE: Verbio adjusts its forecast for the full financial year 2023/24
EQS-Adhoc: Verbio SE: Verbio adjusts its forecast for the full financial year 2023/24